secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001628280-22-021051
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q2 net loss narrows to $26.9M; IBSRELA sales start at $1.6M
-------------------------------------------------------------------

- Net product sales of IBSRELA were $1.6M in Q2 2022, first commercial quarter post-launch.
- Net loss $26.9M ($0.19/share) vs $45.2M ($0.45) in Q2 2021; cash & investments $81.0M.
- Entered $20M financing with HealthCare Royalty based on future royalties from Kyowa Kirin.
- FDA advisory committee for XPHOZAH NDA tentatively scheduled for Nov 16, 2022.
- Survey data: 41% of GIs report using IBSRELA; 92% rate it as a substantial/moderate advance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022021051/0001628280-22-021051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022021051/ardx-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer